Phone:
+1 877 302 8632
Fax:
+1 888 205 9894 (Toll-free)
E-Mail:
orders@antibodies-online.com

Deoxycytidine Kinase (DCK) (Middle Region) Peptide

DCK Reactivity: Human Host: Synthetic BP, WB
Catalog No. ABIN975622

Quick Overview for Deoxycytidine Kinase (DCK) (Middle Region) Peptide (ABIN975622)

Target

DCK (Deoxycytidine Kinase (DCK))

Origin

Human

Source

  • 4
Synthetic

Application

Blocking Peptide (BP), Western Blotting (WB)
  • Protein Region

    Middle Region

    Characteristics

    This is a synthetic peptide designed for use in combination with anti-DCK antibody (Catalog #: ARP51774_P050). It may block above mentioned antibody from binding to its target protein in western blot and/or immunohistochecmistry under proper experimental settings. There is no guarantee for its use in other applications.

    Purification

    Purified
  • Application Notes

    Each Investigator should determine their own optimal working dilution for specific applications.

    Restrictions

    For Research Use only
  • Format

    Lyophilized

    Reconstitution

    Add 100 μL of sterile PBS. Final peptide concentration is 1 mg/mL in PBS.

    Concentration

    1 mg/mL

    Buffer

    Final peptide concentration is 1 mg/mL in PBS.

    Handling Advice

    Avoid repeated freeze-thaw cycles.

    Storage

    -20 °C

    Storage Comment

    For longer periods of storage, store at -20°C. Avoid repeat freeze-thaw cycles.
  • Target

    DCK (Deoxycytidine Kinase (DCK))

    Background

    Deoxycytidine kinase (DCK) is required for the phosphorylation of several deoxyribonucleosides and their nucleoside analogs. Deficiency of DCK is associated with resistance to antiviral and anticancer chemotherapeutic agents. Conversely, increased deoxycytidine kinase activity is associated with increased activation of these compounds to cytotoxic nucleoside triphosphate derivatives. DCK is clinically important because of its relationship to drug resistance and sensitivity.Deoxycytidine kinase (DCK) is required for the phosphorylation of several deoxyribonucleosides and their nucleoside analogs. Deficiency of DCK is associated with resistance to antiviral and anticancer chemotherapeutic agents. Conversely, increased deoxycytidine kinase activity is associated with increased activation of these compounds to cytotoxic nucleoside triphosphate derivatives. DCK is clinically important because of its relationship to drug resistance and sensitivity. Publication Note: This RefSeq record includes a subset of the publications that are available for this gene. Please see the Entrez Gene record to access additional publications.

    Alias Symbols: MGC117410, MGC138632

    Protein Interaction Partner: DDX19B,GOLM1,MED19,DDX19B,GOLM1,MED19

    Protein Size: 260

    Molecular Weight

    30 kDa

    Gene ID

    1633

    NCBI Accession

    NM_000788, NP_000779

    UniProt

    P27707
You are here:
Chat with us!